BioNTech SE (BioNTech SE) Price-to-Tangible-Book

: 1.01 (As of Today)

View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-23), BioNTech SE's share price is $88.64. BioNTech SE's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $87.52. Hence, BioNTech SE's Price to Tangible Book Ratio of today is 1.01.

The historical rank and industry rank for BioNTech SE's Price-to-Tangible-Book or its related term are showing as below:

BNTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1 Med: 4.73 Max: 17.11
Current: 1.01

During the past 8 years, BioNTech SE's highest Price to Tangible Book Ratio was 17.11. The lowest was 1.00. And the median was 4.73.

BNTX's Price-to-Tangible-Book is ranked better than
82.56% of 1221 companies
in the Biotechnology industry
Industry Median: 2.67 vs BNTX: 1.01

A closely related ratio is called PB Ratio. As of today, BioNTech SE's share price is $88.64. BioNTech SE's Book Value per Sharefor the quarter that ended in Dec. 2023 was $92.87. Hence, BioNTech SE's P/B Ratio of today is 0.95.

BioNTech SE Price-to-Tangible-Book Historical Data

The historical data trend for BioNTech SE's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

17.11

13.39

4.73

1.74

1.21

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.74	1.41	1.23	1.28	1.21

Competitive Comparison

For the Biotechnology subindustry, BioNTech SE's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, BioNTech SE's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Price-to-Tangible-Book falls into.

BioNTech SE Price-to-Tangible-Book Calculation

BioNTech SE's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	88.64	/	87.522
	=	1.01

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

BioNTech SE Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.